The Food and Drug Administration, which cut more than 3,000 employees last year, has been authorized to hire 2,200 people, Lowell Zeta, acting chief of staff for the FDA commissioner, said Tuesday at the BIO International Convention in San Diego.
The cuts were part of Health Secretary Robert F. Kennedy Jr.’s effort to reshape federal public health agencies. Former FDA officials warned last year that the reductions could disrupt the agency’s review of applications for new medicines. Some staffers said they were struggling to meet deadlines mandated by Congress because of the layoffs.
“We are going to bring back 2,200, to start,” Zeta said. He said about 600 new employees were in the onboarding process, and a couple hundred had started their new jobs.
The hiring comes as the agency said it would use a more flexible approach to manufacturing cell and gene therapies and announced a new plan to speed early drug development. The FDA also agreed to reassess several drugs for rare diseases that it had previously declined to approve.
“Our execution has changed a bit,” Zeta said.
Former FDA Commissioner Marty Makary resigned in May after weeks of clashing with White House and health advisers and drawing scrutiny for a series of agency decisions.
“We are seeing very significant numbers applying,” said Karim Mikhail, acting director of the FDA’s Center for Biologics Evaluation and Research. He said the agency was also taking steps to keep current employees from leaving.
“There is a lot of effort to minimize attrition,” he said. In some cases, Mikhail said, staff were being temporarily transferred to departments with heavier workloads.